DPP4 and Hyperglycemia: Near-normalization of hyperglycemia through 4 weeks of insulin therapy [173], or through administration of sulphonylurea [174] or DPP4 inhibitor [175] improves the insulinotropic effect of GIP in people living with T2D, supporting that GIPR agonism may offer pharmacological benefits on glucose control when given together with drugs that decrease hyperglycemia.